Cart
sales@molnova.com
(E)-AG 556
CAS No. 133550-41-1
(E)-AG 556( (E)-Tyrphostin AG 556 )
Catalog No. M27474 CAS No. 133550-41-1
AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 42 | Get Quote |
|
| 10MG | 72 | Get Quote |
|
| 25MG | 147 | Get Quote |
|
| 50MG | 222 | Get Quote |
|
| 100MG | 331 | Get Quote |
|
| 200MG | 489 | Get Quote |
|
| 500MG | 777 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name(E)-AG 556
-
NoteResearch use only, not for human use.
-
Brief DescriptionAG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
-
DescriptionAG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.
-
In Vitro——
-
In Vivo——
-
Synonyms(E)-Tyrphostin AG 556
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number133550-41-1
-
Formula Weight336.38
-
Molecular FormulaC20H20N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (297.28 mM)
-
SMILESN#C/C(/C(NCCCCc1ccccc1)=O)=C\c(cc1)cc(O)c1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Qa'dan F, et al. Cinchonain Ib isolated from Eriobotrya japonica induces insulin secretion in vitro and in vivo. J Ethnopharmacol. 2009 Jul 15;124(2):224-7.
molnova catalog
related products
-
Anlotinib
Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
-
PD 089828
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
-
PF-06747775
A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
